SOLRIAMFETOL

Other

Brand names: SUNOSI

Oral

Mechanism of Action

12.1 Mechanism of Action The mechanism of action of solriamfetol to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea is unclear. However, its efficacy could be mediated through its activity as a dopamine and norepinephrine reuptake inhibitor (DNRI).

Indications

See full prescribing information

Contraindications

• 4 CONTRAINDICATIONS SUNOSI is contraindicated in patients receiving concomitant treatment with monoamine oxidase (MAO) inhibitors
• or within 14 days following discontinuation of monoamine oxidase inhibitor
• because of the risk of hypertensive reaction [see Drug Interactions ( 7.1 )] . Concurrent treatment with a monoamine oxidase inhibitor (MAOI) or use of an MAOI within the preceding 14 days. ( 4 )

FDA Warnings

5 WARNINGS AND PRECAUTIONS Blood Pressure and Heart Rate Increases : Measure heart rate and blood pressure prior to initiating and periodically throughout treatment
Avoid use in patients with unstable cardiovascular disease, serious heart arrhythmias, or other serious heart problems
Epidemiological data show that chronic elevations in blood pressure increase the risk of major adverse cardiovascular events (MACE), including stroke, heart attack, and cardiovascular death
The magnitude of the increase in absolute risk is dependent on the increase in blood pressure and the underlying risk of MACE in the population being treated

Known Side Effects

10 documented side effects by frequency

Drug Not Working

>10%

Anxiety

1-10%

Headache

1-10%

Nausea

1-10%

Fatigue

1-10%

Drowsiness

1-10%

Depression

0.1-1%

Dizziness

0.1-1%

Insomnia

0.1-1%

High Blood Pressure

0.1-1%

Community Discussions

No community discussions found for SOLRIAMFETOL yet.

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Oral